During a Case-Based Roundtable® event, Tara K. Gregory, MD, discussed how to implement use of bispecific T-cell engagers in ...

The bispecific T-cell engager tarlatamab showed continued efficacy and tolerable safety, according to follow-up from the ...

The next-generation radiopharmaceutical ABD-147 was previously granted FDA fast track designation in extensive-stage small ...

As oncologists and the healthcare industry advance their practices to propel care for children, it is crucial for the ...

Panelists discuss how a case study illustrates the multisystem manifestations of chronic graft-versus-host disease and demonstrate the application of NIH organ-specific scoring for comprehensive ...

Panelists discuss how chronic graft-versus-host disease severity can be stratified to guide the tailoring of systemic treatments and supportive care strategies for optimal patient management.

Denileukin diftitox, an IL-2-receptor-directed cytotoxin, has been added to the NCCN guidelines for the treatment of adult ...

Pembrolizumab plus concurrent chemoradiotherapy demonstrated a higher progression-free survival rate than placebo plus ...

Ifinatamab deruxtecan, a novel antibody-drug conjugate, returned promising response rates at both dose levels evaluated among ...

Valemetostat showed promise as a treatment option for patients with relapsed/refractory peripheral T-cell lymphoma.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Anil Parwani, MD, PhD, addresses potential biases or limitations in the artificial intelligence algorithm used at his institution.